Friday 6 November 2026
Export ELAN’s income statement to Excel — free account
Elanco Animal Health Incorporated
ELAN Healthcare Drug Manufacturers Specialty & Generic
Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024.
- Revenue
- +11.3%
- EPS
- +157.1%
- Free cash flow
- +35.6%
- Total debt
- −6.91%
Quarter to September 2026, against a year earlier
23.74
1.57
−6.20%
Follow ELAN
Alert me
| Sep '26 From the 10-Q filed 6 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 5 | 5 | 5 |
+8 more TTM periods Free account |
| (2.20%) | (2.98%) | (3.77%) | (3.67%) | ||
| (1.09%) | (1.46%) | (1.85%) | (1.79%) | ||
ROIC |
0.00% | 0.51% | 0.35% | 0.09% | |
Return on Tangible Assets |
(4.35%) | (5.93%) | (7.30%) | (7.09%) | |
Average Days of Receivables |
75.37 | 83.76 | 86.08 | 72.77 | |
Free Cash Flow per Share |
0.82 | 0.76 | 0.63 | 0.57 | |
Free Cash Flow |
408.00 | 379.00 | 315.00 | 284.00 | |
Capital Expenditures |
(206.00) | (238.00) | (262.00) | (276.00) | |
| Other line items | |||||
Cash ROIC |
5.75% | 3.43% | 2.88% | 2.56% | |
Accounts Receivable Turnover |
5.05 | 4.45 | 4.42 | 5.16 | |
Accounts Payable Turnover |
5.88 | 5.64 | 6.27 | 6.39 | |
Inventory Turnover |
1.28 | 1.30 | 1.33 | 1.28 | |
Average Days of Payables |
67.31 | 69.55 | 61.75 | 63.30 | |
Days of Inventory on Hand |
294.14 | 288.12 | 285.00 | 298.78 | |
Tax Rate |
0.60 | 0.20 | 0.23 | 0.04 | |
Research and Development Expense of Revenue |
7.40% | 7.39% | 7.58% | 7.80% | |
Selling, General and Administrative Expense of Revenue |
30.32% | 30.26% | 30.04% | 30.33% | |
Share Based Compensation of Revenue |
1.50% | 1.47% | 1.51% | 1.44% | |
Interest Coverage |
0.00 | 0.33 | 0.24 | 0.07 | |
Operating CF/Net income |
(4.18) | (3.10) | (2.38) | (2.41) | |
Depreciation/Fixed assets |
0.48 | 0.49 | 0.50 | 0.48 | |
Capex/Depreciation |
(0.30) | (0.34) | (0.38) | (0.41) | |
Revenue per Share |
10.30 | 10.05 | 9.83 | 9.50 | |
Operating CF per Share |
1.23 | 1.24 | 1.16 | 1.13 | |
Capex per Share |
(0.41) | (0.48) | (0.53) | (0.56) | |
Capex to Sales |
0.04 | 0.05 | 0.05 | 0.06 |
Columns are period end dates · fundamentals updated 6 Nov 2026